---
title: 'INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment
  of H3-mutated diffuse midline gliomas'
date: '2023-10-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37853454/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231019180803&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Diffuse midline gliomas (DMG) are universally lethal central
  nervous system tumors that carry almost unanimously the clonal driver mutation histone-3
  K27M (H3K27M). The single amino acid substitution of lysine to methionine harbors
  a neoantigen that is presented in tumor tissue. The long peptide vaccine H3K27M-vac
  targeting this major histocompatibility complex class II (MHC class II)-restricted
  neoantigen induces mutation-specific immune responses that suppress the growth ...'
disable_comments: true
---
INTRODUCTION: Diffuse midline gliomas (DMG) are universally lethal central nervous system tumors that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M). The single amino acid substitution of lysine to methionine harbors a neoantigen that is presented in tumor tissue. The long peptide vaccine H3K27M-vac targeting this major histocompatibility complex class II (MHC class II)-restricted neoantigen induces mutation-specific immune responses that suppress the growth ...